Fulgent Q1 2024 core revenue $63.2M (+1% YoY), GAAP loss $0.45/share, reiterates FY guidance

Fulgent Genetics, Inc.

Total revenue $64.5M; core revenue $63.2M (+1% YoY); FY2024 core revenue guidance reiterated at $280M.
GAAP net loss $13.5M ($0.45 diluted loss per share); Non-GAAP loss $269K ($0.01 per share).
Adjusted EBITDA loss $3.2M; cash from operations $7.3M in Q1.
Cash, cash equivalents, and marketable securities $846.2M as of March 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Fulgent Genetics, Inc. reported first quarter ended March 31, 2024 results: revenue $64.5 million, net income loss of $13.5 million, EPS $0.45 per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $64.5 million
Net income: loss of $13.5 million
EPS: $0.45 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Fulgent Reports First Quarter 2024 Financial Results • Total Revenue of $64.5 million • Core Revenue grows 1% year-over-year to $63.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-052481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.